NoaBiranMD

Oncology • Hackensack, NJ

Hematologic Oncology

Physician

Join to view full profile

Dr. Biran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Biran's full profile

Already have an account?

Office
92 2nd Street
Hackensack, NJ 07601
Is this information wrong?

Summary

Dr. Noa Biran is an oncologist in Hackensack, NJ and is affiliated with Hackensack Meridian Health Hackensack University Medical Center. She received her medical degree from George Washington University School of Medicine and has been in practice 9 years. She specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.

As a physician in the Myeloma Division at John Theurer Cancer Center, my research is focused on high-risk multiple myeloma patients with refractory disease, many of whom have been through multiple lines of treatment. Our most promising therapy at this time is BCMA directed CAR-T cell therapy, which uses T-cells that are reengineered to target multiple myeloma. The response rate has been close to 80% in some. We are also exploring other drug therapies, including genetic approaches to treatment, and starting to move these treatment strategies to earlier in the patient’s therapy in the hopes of generating a longer remission.

Noa Biran, M.D., works with a dedicated team that specializes in the treatment o

Dr. Noa Biran, physician in the Myeloma Division at John Theurer Cancer Center, works with a dedicated team that specializes in the treatment of multiple my...

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2011 - 2014
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2008 - 2011
George Washington University School of Medicine and Health SciencesClass of 2008

Certifications & Licensure

NY State Medical License 2009 - 2026
NJ State Medical License 2014 - 2025
PA State Medical License 2023 - 2024

Clinical Trials

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma Start of enrollment: 2010 Apr 08
Completed
Phase 3
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 1, Phase 2
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older Start of enrollment: 2010 Jun 24
Terminated
Phase 2
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 Nov 01
Terminated
Phase 1, Phase 2
Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Selinexor and Backbone Treatments of Multiple Myeloma Patients Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 1, Phase 2
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence Start of enrollment: 2016 Jun 07
Terminated
Phase 1, Phase 2
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant Start of enrollment: 2019 Mar 08
Terminated
Phase 1
PRospective Multiple Myeloma Impact Study Start of enrollment: 2018 Feb 27
Active, not recruiting
Not Applicable
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2018 Feb 01
Completed
Phase 1, Phase 2
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation Start of enrollment: 2018 Jul 02
Active, not recruiting
Phase 2
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Start of enrollment: 2020 Jun 30
Active, not recruiting
Phase 1, Phase 2
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma Start of enrollment: 2022 May 02
Terminated
Phase 2
Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2017 Oct 04
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma Start of enrollment: 2022 Dec 08
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

9 citations
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.
Paul G Richardson, Sundar Jagannath, Ajai Chari, Dan T Vogl, Meletios A Dimopoulos
Ejhaem. 2021-02-01
198 citations
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.
Noa Biran, Andrew Ip, Jaeil Ahn, Ronaldo C. Go, Shuqi Wang
The Lancet. Rheumatology. 2020-10-01
101 citations
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Andrew Ip, Donald A. Berry, Eric Hansen, Andre Goy, Andrew L. Pecora
Plos One. 2020-08-13

Journal Articles

Tocilizumab Among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational Study
Noa Biran, Andrew Ip, Ronaldo Collo Go, The Lancet Rheumatology

Abstracts/Posters

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Noa Biran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Building a National CML Registry
Noa Biran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
Noa Biran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)
Noa Biran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma
Noa Biran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
Noa Biran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Noa Biran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Noa Biran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Noa Biran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Authored Content

Tocilizumab Among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational StudyAugust 2020
Tocilizumab Among Patients with COVID-19 in the Intensive Care Unit: A Multicentre Observational StudyAugust 2020

Press Mentions

John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual ConferenceDecember 9th, 2021
John Theurer Cancer Center (JTCC) Researchers to Present 52 Abstracts Across Hematological Malignancies at the 2020 American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 4th, 2020
Dr. Biran on Post-ASCT Consolidation in Multiple MyelomaJanuary 31st, 2020
Join now to see all